IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir
Date
2017Journal
GastroenterologyPublisher
W.B. SaundersType
Article
Metadata
Show full item recordKeyword
HepacivirusCarbamates--administration & dosage
Hepatitis C, Chronic--genetics
Heterocyclic Compounds, 4 or More Rings--administration & dosage*
Interleukins--analysis
Macrocyclic Compounds--administration & dosage
Sofosbuvir--administration & dosage
Sulfonamides--administration & dosage
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85035029912&doi=10.1053%2fj.gastro.2017.06.069&partnerID=40&md5=2498d61cc0b9f11975f8c572161c1aac; http://hdl.handle.net/10713/11082ae974a485f413a2113503eed53cd6c53
10.1053/j.gastro.2017.06.069
Scopus Count
Collections
Related articles
- Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
- Authors: Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C, Gutierrez J
- Issue date: 2017 Jun
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
- Authors: Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR
- Issue date: 2017 Jul
- Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
- Authors: Younossi ZM, Stepanova M, Jacobson IM, Asselah T, Gane EJ, Lawitz E, Foster GR, Roberts SK, Thompson AJ, Willems BE, Welzel TM, Pearlman B, Younossi I, Racila A, Henry L
- Issue date: 2018 Jan
- Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
- Authors: Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M
- Issue date: 2019 Oct
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
- Authors: Heo YA, Deeks ED
- Issue date: 2018 Apr